Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Mesenchymal Stem Cells-Potential Applications in Kidney Diseases.

Bochon B., Kozubska M., Surygała G., Witkowska A., Kuźniewicz R., Grzeszczak W.

Clinical Trial on Chronic Kidney Disease, Acute Kidney Injury, Immune Modulation, Autoimmune Research, published in Int J Mol Sci (2019) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int J Mol Sci (2019)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
31109047
DOI
10.3390/ijms20102462

Abstract (original English)

Mesenchymal stem cells constitute a pool of cells present throughout the lifetime in numerous niches, characteristic of unlimited replication potential and the ability to differentiate into mature cells of mesodermal tissues in vitro. The therapeutic potential of these cells is, however, primarily associated with their capabilities of inhibiting inflammation and initiating tissue regeneration. Owing to these properties, mesenchymal stem cells (derived from the bone marrow, subcutaneous adipose tissue, and increasingly urine) are the subject of research in the settings of kidney diseases in which inflammation plays the key role. The most advanced studies, with the first clinical trials, apply to ischemic acute kidney injury, renal transplantation, lupus and diabetic nephropathies, in which beneficial clinical effects of cells themselves, as well as their culture medium, were observed. The study findings imply that mesenchymal stem cells act predominantly through secreted factors, including, above all, microRNAs contained within extracellular vesicles. Research over the coming years will focus on this secretome as a possible therapeutic agent void of the potential carcinogenicity of the cells.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsBone Marrow CellsCell DifferentiationDiabetic NephropathiesExosomesExtracellular VesiclesGlomerulonephritisHumansImmunomodulationKidney Diseases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research